<DOC>
	<DOCNO>NCT02643550</DOCNO>
	<brief_summary>The objective study evaluate 3 +3 design , safety escalate dos IPH2201 give IV combination cetuximab patient receive prior systemic regimen ( ) recurrent and/or metastatic squamous cell carcinoma head neck ( SCCHN ) . A cohort expansion evaluate antitumor activity combination .</brief_summary>
	<brief_title>Study IPH2201 ( Monalizumab ) Cetuximab Patients With Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Histologically cytologicallyconfirmed , HPV ( + ) HPV ( ) squamous cell carcinoma nasopharynx ( WHO Type 1 ) , oropharynx , hypopharynx , larynx ( supraglottis , glottis , subglottis ) oral cavity , 3 . Recurrent metastatic disease , document imaging ( CT scan , MRI , Xray ) and/or physical examination . In phase II , measurable disease per Response Evaluation Criteria Solid Tumors [ RECIST ] 1.1 mandate . In phase Ib , patient without measurable disease eligible . 4 . Progression platinumbased chemotherapy 5 . For phase Ib : Pretreated patient , amenable therapy curative intent . This part open pretreated patient regardless number previous treatment line . For phase II : Patients receive maximum two prior systemic regimen recurrent and/or metastatic disease amenable therapy curative intent . 6 . No prior treatment cetuximab except give primary treatment ( locally advance disease ) progressive disease least 4 month follow end prior cetuximab treatment . 7 . Recovery prior surgery recovery adverse event grade 1 less ( except alopecia ) due prior radiation therapy systemic therapy . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 9 . Life expectancy ≥ 3 month 10 . Patients treat brain metastasis eligible &gt; 4 week therapy completion ( include radiation and/or surgery ) , clinically stable time study entry receive corticosteroid therapy time study entry 11 . Adequate hematologic , immunologic , liver renal function , define hemoglobin ≥ 9.0 g/dL , absolute neutrophil count ≥ 1,500/mm3 , platelet ≥ 100,000/mm3 , total bilirubin ≤ 1.5 X institutional upper normal limit ( UNL ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 X institutional UNL , serum creatinine ≤1.5 X institutional UNL estimate ( CockcroftGault formula ) measure creatinine clearance ≥ 50 mL/min 12 . Negative serum pregnancy test within 72 hour start study treatment woman childbearing potential . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration monalizumab administration 5 month last dose monalizumab . 13 . Ability understand write informed consent document 14 . Signed informed consent prior protocolspecific procedure 1 . For phase II : Patients receive 2 prior systemic regimen recurrent and/or metastatic disease ( restriction phase Ib part trial ) . 2 . For phase II : Patients receive cetuximab another inhibitor epidermal growth factor receptor exclude phase II trial , except cetuximab give part primary treatment approach , progressive disease least 4 month follow end prior cetuximab treatment . 3 . History allergic reaction attribute compound similar chemical biologic composition cetuximab . 4 . Patients know untreated uncontrolled brain metastasis exclude . However , brainimaging study require eligibility patient neurological sign symptom . 5 . Serious concurrent uncontrolled medical disorder . 6 . Autoimmune disease , : 1. currently previously require systemic immunosuppressive immunomodulatory therapy ( include corticosteroid administer systemic route ) and/or 2. substantial probability cause irreversible injury tissue and/or 3. diagnose less 3 month study entry and/or 4. clinically unstable and/or 5. substantial risk progress cause severe complication . 7 . Abnormal cardiac status follow : 1 . Unstable angina 2 . Arrhythmia require treatment stabilize treatment 3 . QTc &gt; 450 m ( M ) 470 m ( F ) ( Bazett formula QT Interval / √ ( RR interval ) RR Interval = 60/HR ) . 8 . History cardiac dysfunction include follow : 1 . Myocardial infarction within last 6 month 2 . History document congestive heart failure ( New York Heart Association functional classification IIIIV ) . 9 . Known interstitial lung disease . 10 . Pregnant woman exclude study ; breastfeed must discontinue . 11 . Other active invasive malignancy ( except treat basal squamous cell skin carcinoma , situ cervix carcinoma ) . 12 . Treatment investigational agent le 14 day prior study entry . 13 . Systemic treatment steroid immunosuppressive agent within 30 day prior entry . Physiological replacement hydrocortisone equivalent acceptable . 14 . Current active infectious disease . 15 . Positive serology HIV . 16 . Positive HBs Ag positive HBV viremia , Positive HCV viremia . 17 . Psychological , familial , sociological , geographical condition permit medical followup compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>